Skip to main content
. Author manuscript; available in PMC: 2019 Jul 19.
Published in final edited form as: Pediatr Res. 2019 Jan 19;85(5):602–606. doi: 10.1038/s41390-019-0305-z

Figure 1:

Figure 1:

Logistic regression of adverse events during risperidone treatment in children. Shown are the adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for CYP2D6 poor/intermediate vs. normal/ultrarapid metabolizers, adjusted by risperidone dose, age at start of risperidone, sex, and race